Log in

Relevant bibliographies by topics / Anti-Xa levels

Contents

Journal articles
Books
Book chapters
Conference papers

Academic literature on the topic 'Anti-Xa levels'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti-Xa levels.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anti-Xa levels"

1

Kufel, Wesley D., Robert W. Seabury, William Darko, Luke A. Probst, and Christopher D. Miller. "Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting it Right?" Hospital Pharmacy 52, no. 3 (2017): 214–20. http://dx.doi.org/10.1310/hpj5203-214.

Full text

Abstract:

Background Anti-Xa monitoring is utilized to measure the extent of anticoagulation in certain patient populations receiving enoxaparin. It is essential to accurately obtain this pharmacodynamic marker for safe and effective anticoagulation management. Objectives To determine the frequency of correctly drawn anti-Xa concentrations in accordance with predefined institutional criteria and to determine the number of dose adjustments implemented based on incorrectly drawn anti-Xa concentrations. Methods This was a retrospective, single-center, cohort study among adult patients who received treatmen

APA, Harvard, Vancouver, ISO, and other styles

2

Perkins, Louis, Laura Adams, Dmitri Lerner, Jarrett Santorelli, Alan M. Smith, and Leslie Kobayashi. "Predictors of direct oral anticoagulant concentrations in the trauma population." Trauma Surgery & Acute Care Open 9, no. 1 (2024): e001208. http://dx.doi.org/10.1136/tsaco-2023-001208.

Full text

Abstract:

IntroductionDirect oral anticoagulant (DOAC) use is becoming more prevalent in patients presenting after trauma. We sought to identify the prevalence and predictors of subtherapeutic and therapeutic DOAC concentrations and hypothesized that increased anti-Xa levels would correlate with increased risk of bleeding and other poor outcomes.MethodsA retrospective cohort study of all trauma patients on apixaban or rivaroxaban admitted to a level 1 trauma center between January 2015 and July 2021 was performed. Patients were excluded if they did not have a DOAC-specific anti-Xa level at presentation.

APA, Harvard, Vancouver, ISO, and other styles

3

Fung, Lela S., and Christopher Klockau. "Effects of Age and Weight-Based Dosing of Enoxaparin on Anti-Factor Xa Levels In Pediatric Patients." Journal of Pediatric Pharmacology and Therapeutics 15, no. 2 (2010): 119–25. http://dx.doi.org/10.5863/1551-6776-15.2.119.

Full text

Abstract:

ABSTRACT OBJECTIVE The objective of this dose range study is to expand on the relationship between age and weight-based doses of enoxaparin and resulting levels of anti-factor Xa (anti-Xa) in pediatric patients. The primary outcome of this study is to determine the average dose of enoxaparin required to produce a therapeutic effect. Secondary outcomes include the number of enoxaparin dose changes required to achieve a therapeutic level of anti-Xa in each age group, the success rates of achieving and maintaining therapeutic anti-Xa levels, and the effect of serum antithrombin concentrations on

APA, Harvard, Vancouver, ISO, and other styles

4

Kuitunen, Anne, Jari Petäjä, Sorella Ilveskero, Riitta Lassila, and Peter Raivio. "Monitoring high-dose heparinization during cardiopulmonary bypass – A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays." Thrombosis and Haemostasis 99, no. 02 (2008): 427–34. http://dx.doi.org/10.1160/th07-04-0307.

Full text

Abstract:

SummaryHeparinization requires monitoring, but optimal methods for measuring the anticoagulant effects of heparin remain to be determined. We compared prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity (anti-Xa) assays in monitoring high-dose heparinization during cardiopulmonary by-pass (CPB). Heparin effects were serially measured with PiCT and two anti-Xa assays in 100 patients. Antithrombin and protein C activities were measured preoperatively, and antithrombin activity was measured during CPB. Activation of coagulation was assessed with measurements of

APA, Harvard, Vancouver, ISO, and other styles

5

Huh, Jin-Hyeun, Derek Leong, Maxine Lau, and Maja Gavrilovic. "Validation of a Weight Based Heparin Nomogram That Utilizes Anti-Factor Xa Levels for Monitoring." Blood 108, no. 11 (2006): 4114. http://dx.doi.org/10.1182/blood.v108.11.4114.4114.

Full text

Abstract:

Abstract PURPOSE: This study documented consecutive patients receiving continous intravenous (IV)unfractioned heparin(UFH) infusion during the introduction of an Anti-Xa level and weight based nomogram to evaluate 1)the ability of the new nomogram to achieve a therapeutic Anti-Xa level with the first level drawn. 2) the ability of the new nomogram to achieve Anti-Xa levels within the therapeutic range by 24 hours from initiation. After review of the current literature, the therapeutic anti-Xa level were defined as 0.4–0.6 and 0.4–0.5 for standard and low dose anticoagulation respectively. METH

APA, Harvard, Vancouver, ISO, and other styles

6

Wahking, Rebekah A., Rachel H. Hargreaves, Sean M. Lockwood, Sabrina K. Haskell, and Kelly W. Davis. "Comparing Anti–Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin." Annals of Pharmacotherapy 53, no. 8 (2019): 801–5. http://dx.doi.org/10.1177/1060028019835202.

Full text

Abstract:

Background: Lab tests such as activated partial thromboplastin time (aPTT) or anti–factor Xa (anti-Xa) levels are typically used to monitor intravenous unfractionated heparin (IV heparin), with recent evidence suggesting that anti-Xa levels may provide a more accurate measure of anticoagulation. Objective: The Lexington Veterans Affairs Health Care System transitioned from using aPTT to anti-Xa levels in January 2017. This study was conducted to evaluate the efficacy and safety of this change. Methods: This was a retrospective cohort study comparing all patients receiving IV heparin per protoc

APA, Harvard, Vancouver, ISO, and other styles

7

Levine, Mark, Michael Keeney, Karen MacKinnon, Agnes Lee, and Michael Kovacs. "Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients." Thrombosis and Haemostasis 93, no. 06 (2005): 1185–88. http://dx.doi.org/10.1160/th05-01-0052.

Full text

Abstract:

SummaryMany patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time. It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods. This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer. Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin (200 IU per kilogram

APA, Harvard, Vancouver, ISO, and other styles

8

Niziolek, Grace Martin, Lauren Mangan, Cassidi Weaver, et al. "Inadequate prophylaxis in patients with trauma: anti-Xa-guided enoxaparin dosing management in critically ill patients with trauma." Trauma Surgery & Acute Care Open 9, no. 1 (2024): e001287. http://dx.doi.org/10.1136/tsaco-2023-001287.

Full text

Abstract:

IntroductionVenous thromboembolism (VTE) causes significant morbidity in patients with trauma despite advances in pharmacologic therapy. Prior literature suggests standard enoxaparin dosing may not achieve target prophylactic anti-Xa levels. We hypothesize that a new weight-based enoxaparin protocol with anti-Xa monitoring for dose titration in critically injured patients is safe and easily implemented.MethodsThis prospective observational study included patients with trauma admitted to the trauma intensive care unit (ICU) from January 2021 to September 2022. Enoxaparin dosing was adjusted bas

APA, Harvard, Vancouver, ISO, and other styles

9

Effendi, Muhammad, Martha Stutsky, Caleigh A. Curran, Kent A. Owusu, and Alfred Ian Lee. "Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns." Blood 132, Supplement 1 (2018): 2284. http://dx.doi.org/10.1182/blood-2018-99-119379.

Full text

Abstract:

Abstract Introduction: Low molecular weight heparin (LMWH) has a favorable pharmacokinetic profile which precludes the need for routine laboratory monitoring. However, certain patient populations, including those with extreme body weight (overweight or underweight), renal dysfunction, history of bleeding event while receiving LMWH, or previous failure of therapy, may benefit from therapeutic monitoring. Suboptimal drug monitoring of enoxaparin due to incorrect timing of anti-Xa levels, delayed blood sample draws, and/or lack of follow up once the anti-Xa level has resulted has been documented

APA, Harvard, Vancouver, ISO, and other styles

10

Papadakis, Ioannis, Andria Papazachariou, Aikaterini Charizani, et al. "INFLUENCE OF VARIOUS FACTORS ON ANTI-XA LEVELS IN HOSPITALIZED MEDICAL PATIENTS RECEIVING PARENTERAL THROMBOPROPHYLAXIS." Journal of Hypertension 42, Suppl 1 (2024): e274. http://dx.doi.org/10.1097/01.hjh.0001022320.69726.4c.

Full text

Abstract:

Objective: Venous thromboembolism (VTE) stands as a prevalent vascular disease, intimately linked to increased risk for morbidity and mortality. The aim of this study was to investigate the influence of various factors on anti-Xa levels in hospitalized medical patients receiving parenteral thromboprophylaxis. Design and method: This is a single-center cohort study encompassing patients admitted to the Internal Medicine Department of the University Hospital of Heraklion, from March to August 2023. These patients were placed on thromboprophylaxis due to a heightened risk of developing VTE. Data

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Anti-Xa levels"

1

Fan-Lun, Chris. Analysis of anti-xa levels in deep venous thrombosis (DVT) patirnts treated with dalteparin (Fragmin). 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Anti-Xa levels"

1

Downing, Jessica, Meaghan Keville, and Daniel Haase. "Reversal agents: Antidotes for anticoagulants." In Critical Care Emergencies, edited by Lillian Liang Emlet. Oxford University PressNew York, 2023. http://dx.doi.org/10.1093/med/9780190082581.003.0027.

Full text

Abstract:

Abstract Emergency management of the hemorrhaging patient with anticoagulant-induced coagulopathy medications is becoming increasingly complex with the introduction of various direct-acting oral anticoagulant (DOAC) agents such as dabigatran, rivaroxaban, apixaban, and edoxaban. Detecting the presence, type, or therapeutic effect of DOACs is challenging. Routine laboratory testing (PT, PTT, INR) does not accurately reflect their therapeutic levels or the extent of coagulopathy, so advanced anticoagulation testing (TT, dTT, anti-Xa, TEG, ROTEM) is often necessary. Undifferentiated patients with

APA, Harvard, Vancouver, ISO, and other styles

2

Paternoster, Gianluca, Marc O. Maybauer, and Filippo Sanfilippo. "Heparin Anticoagulation for Transcatheter Aortic Valve Implantation on ECMO." In Extracorporeal Membrane Oxygenation, edited by Marc O. Maybauer. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197521304.003.0013.

Full text

Abstract:

Extracorporeal membrane oxygenation (ECMO) is a life-saving intervention option for critically ill patients with cardiac and/or respiratory failure. Worldwide many medical centers started to use ECMO as a rescue treatment option when conventional therapies failed. This chapter describes conventional strategies of anticoagulation for ECMO. Indeed, during ECMO support the continuous flow and the contact between the patient’s blood and nonbiological surfaces such as cannulae or the oxygenator triggers the activation of the coagulation cascade, with formation of clots and consumption of coagulatio

APA, Harvard, Vancouver, ISO, and other styles

3

van Mens, Thijs E., and Saskia Middeldorp. "Management of pulmonary embolism in pregnancy." In ESC CardioMed. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0665.

Full text

Abstract:

Pulmonary embolism, although rare, is a leading cause of maternal mortality. There is no strong evidence base for the diagnosis and management of pregnancy-related pulmonary embolism, hampering firm recommendations. In women with a suspicion of pulmonary embolism, the diagnosis is confirmed in 1 in 25–30 women only. However, imaging is always necessary to exclude pulmonary embolism, as no clinical decision rules or D-dimer-based strategies have been validated in pregnancy. Computed tomography pulmonary angiography and pulmonary scintigraphy are both suitable modalities, unless deep vein thromb

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anti-Xa levels"

1

Albada, J., K. K. Nieuwenhuis, and J. J. Sixma. "PHARMACOKINETICS OF A LOW MOLECULAR WEIGHT HEPARIN (KABI 2165, FRAGMIN) ATFER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION IN HUMAN VOLUNTEERS AND ITS IN VIVO NEUTRALIZATION BY PROTAMINE SULFATE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642866.

Full text

Abstract:

Pharmacokinetics of a low molecular weight heparin (LMWH) were studied in healthy volunteers. After an intravenous bolus injection of 5000 anti-Xa U in 5 healthy volunteers anti Xa activity disappeared according to the combination of saturable and a linear mechanism, preceded by a rapid initial disappearance. The apparent half-life of the anti Xa activity is about twice as long as that of standard heparin. In another set of experiments 5000 anti Xa U of LMWH were immediately followed by 50 mgr of Protamine Sulphate (PS). The curve of the anti Xa-activity parallelled the original curve at a lev

APA, Harvard, Vancouver, ISO, and other styles

2

Ireland, H., D. A. Lane, A. M. Flynn, A. C. Pegrum, and J. R. Curtis. "DOSE FINDING STUDY OF LOW MW HEPARIN (LMWH) CY222 IN HAEMODIALYSIS FOR CHRONIC RENAL FAILURE: RELATIONSHIP BETWEEN ANTI-FACTOR XA ACTIVITY AND ANTICOAGULANT EFFECT." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643231.

Full text

Abstract:

A dose finding study of the LMWH CY222 (MLT2800) in patients (n=8) has been carried out to < i ) establish an effective dose and <ii) determine the relationship between ex vivo anti-factor Xa levels in plasma and the anticoagulant effect (in vivo suppression of FPA levels). Doses of CY222 were compared to a dose <5000 iu bolus+1500 iu/hr) of unfractionated heparin (UFH) that has been shown to suppress FPA levels during prolonged <>5hr) dialysis (Ireland et al , J Lab Clin Med 103, 643, 1984). CY222 given iv in doses (a) 5000 IC (Institute Choay)u bolus+1500 ICu/hr (b) 10000 IC b

APA, Harvard, Vancouver, ISO, and other styles

3

Scully, M. F., H. A. Decousus, V. Ellis, P. Girard, C. Parker, and V. V. Kakkar. "MEASUREMENT OF HEPARIN IN PLASMA: INFLUENCE OF INTER-SUBJECT AND CIRCADIAN VARIABILITY IN HEPARIN SENSITIVITY ACCORDING TO METHOD." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644165.

Full text

Abstract:

Heparin was measured, with respect to standard curves prepared with normal pooled plasma, by five methods, APTT, (Auto-APTT), thrombin time (Thromboquik), one (Heptest) and two-stage (Hepaclot) coagulation, anti-factor Xa and chromogenic anti-factor Xa after addition at three concentrations (0.2, 0.4, 0.6iu/ml) to plasma prepared from three groups of ten individuals: normal young volunteers, hospitalized patients with malignancy and hospitalized geriatric patients. By the APTT and TT, differences in sensitivity were observed, for example, at 0.4iu heparin/ml corresponding to an apparent differ

APA, Harvard, Vancouver, ISO, and other styles

4

ten Cate, H., Ch P. HENNY, A. Sturk, A. Prins, and J. W. ten Cate. "COMPARATIVE INVESTIGATION OF CLOTTING AND CHROMOGENIC ASSAYS FOR HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN-(OID) IN PLASMA OF VOLUNTEERS AND PATIENTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644166.

Full text

Abstract:

Two recently developed and simplified anti-Xa methods, a chromogenic assay and a clot-based assay (Heptest) were investigated on their accuracy and ex-vivo characteristics. The coefficients of variation (c.v.) for heparin, a heparin fragment (K 2165) and a LMW hepa-rinoid (Org 10172) were respectively: Heptest, within assay c.v.: 5.4; 4.5; 5.0 % between-assay c.v.: 7.8; 5.8; 9.5 %. Chromogenic Anti-Xa assay, within assay c.v.: 3.7; 5.6; 4.6 %, between assay c.v.: 6.6; 8.2; 12.1 %. In plasma samples obtained from volunteers and patients who participated in clinical studies using heparin, K 2165

APA, Harvard, Vancouver, ISO, and other styles

5

Racanelli, A., and J. Fareed. "DIFFERENTIAL NEUTRALIZATION OF UNFRACTIONATED HEPARIN (UH) AND LOW MOLECULAR WEIGHT HEPARINS (LMWHS) BY HUMAN PLATELET FACTOR FOUR (PF-4)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643502.

Full text

Abstract:

Platelet factor 4 neutralization profiles of four newly developed LMWHs, PK 10169 (Pharmuka, Gennevilliers, France) CY 216 (Choay, Paris, France), KABI 2165 (KabiVitrum, Stockholm, Sweden), OP 2123 (Opocrin, Corlo Italy) and an unfractionated porcine mucosal heparin were studied utilizing amidolytic (anti-factor Xa, anti-factor Ila) and clot based (APTT, Heptest ) assays. The neutralization studies were carried out in normal human pooled plasma in two experimental protocolsIn one set of experiments, PF-4 (10μg/ml) was added to varying amounts of UH or LMWH (10-2.5 μg/ml). In the second set of

APA, Harvard, Vancouver, ISO, and other styles

6

Potron, G., O. Toupance, C. Droulle, J. Chanard, A. Kher, and P. Barbier. "USE OF A LOW MOLECULAR WEIGHT HEPARIN (LMWH) KABI 2165 DURING HAEMODIALYSIS : DETERMINATION OF LOWEST EFFECTIVE DOSE-MEMBRANE DEPENDANT DOSAGE REGIMEN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643221.

Full text

Abstract:

The L.M.W.H., Kabi 2165 was compared to standard heparin in stable chronic haemodialysis patients in order to determine the lowest effective dose.An initial dose of 1,000 to 2,500 anti-Xa units followed by an additional dose of 750 to 1,500 anti-Xa units, 1 or 2 hours after the start of the c’alysis was associated with clotting and bleeding complications on 156 dialysis performed in 8 patients: 33 partial coagulations of extracorporeal circulation and 16 minor bleeding events. This dosage regimen corresponds to half of that of standard heparin needed in the same patients to prevent clinical pr

APA, Harvard, Vancouver, ISO, and other styles

7

Walenga, J. M., J. Fareed, M. Petitou, J. C. Lormeau, M. Samama, and J. Choay. "ANTITHROMBOTIC ACTIVITY OF A SYNTHETIC HEPARIN PENTASACCHARIDE IN A RABBIT STASIS THROMBOSIS MODEL USING DIFFERENT THROMBOGENIC CHALLENGES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644161.

Full text

Abstract:

The synthetic pentasccharide, representing the critical sequence required in heparin for binding to antithrombin III, provides a unique tool to study the question of whether an agent solely capable of inhibiting factor Xa but devoid of anti-factor Ila activity in vitro, has the capacity to produce an antithrombotic effect in vivo. We have previously demonstrated in a rabbit stasis thrombosis model using a human serum challenge, a significant antithrombotic effect of the pentasaccharide (Walenga et al., Thromb Res 43:243, 1986). To extend and confirm these studies, four modifications of the sta

APA, Harvard, Vancouver, ISO, and other styles

8

Berruyer, M., and M. Dechavanne. "HAEMOSTASIS CHANGES FOLLOWING TOTAL HIP REPLACEMENT IN A RANDOMIZED TRIAL WITH LMW HEPARIN (KABI 2165) AND ADJUSTED DOSE STANDARD HEPARIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643218.

Full text

Abstract:

70 patients were randomized to 3 groups. Group I : patients received 5,000 IU calciparineR subcutaneously given 2h before operation, twice a day for 3 days and then, doses were adjusted ty heparin levels. Groups II and III : 2,500 IU Kabi 2165 were given instead of calciparineR, but in group III, a single daily dose of 5,000 IU Kabi 2165 was administered from the third day. Fibrino-peptide A (FPA), FPA generation, D-dimers were measured in plasma by ELISA methods. Anti Xa activity, Xa generation, heparin cofactor II (HC II), antithrombin III (AT III) were assayed in plasma using amidolytic met

APA, Harvard, Vancouver, ISO, and other styles

9

Decousus, H. A., M. F. Scully, J. Reynaud, et al. "CIRCADIAN CHANGES IN THE ANTICOAGULANT EFFECT OF HEPARIN. PHARMACODYNAMIC AND PHARMACOKINETIC EFFECT." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644175.

Full text

Abstract:

Six patients, with thromboembolic arterial disease, were prospectively studied to assess the influence of the time of injection of a constant dose of calcium heparin (Choay ), given subcutaneously, on the level of heparin measured by APTT and anti-Xa assay. For each patient, the initial dose of heparin was adjusted by APTT 6h after a morning injection to 1.5 and 2.5 times control. Dose was then kept constant. Four randomized times of injection were tested (8am, 4pm, 8pm and 12pm), in each patient acting as his own control. Blood was sampled via a cannula, at Oh, 2h, 3h,4h,5h,6h, 8h, lOh and 12

APA, Harvard, Vancouver, ISO, and other styles

10

DELAHOUSSE, B., Y. GRUEL, P. MOALIC, L. QUILLIET, F. TOULEMONDE, and J. LEROY. "MODIFICATIONS OF BIOLOGICAL PARAMETERS DURING TREATMENT OF PULMONARY EMBOLISM BY A VERY LOW MOLECULAR HEPARIN FRAGMENT (CY 222)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643230.

Full text

Abstract:

45 patients with pulmonary embolism (PE) were treated by a very low molecular weight heparin fragment (CY 222, Institut CHOAY - France) in an open range dose study. Patients were included into three groups (I, II and III) and received respectively 500, 750 or 1000 IC (Institut Choay) antiXa units/ kg/day by continuous intravenous infusion for ten days. The laboratory screen carried out at Day 0 and at 2 - 8 - 12 - 24 - 36, 48 hours and then every day until Day 10, included : Platelet count, Thromboelastography (TEG) on platelet rich plasma (PRP), Amidolytic assays for anti Xa (CBS 3139 STAGO)

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!